Impact on quality of life from multimodality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial)
Authors
Taylor, SallyYorke, Janelle
Tsim, S.
Navani, N.
Baldwin, D.
Woolhouse, I.
Edwards, J.
Grundy, S.
Robson, J.
Rhodes, S.
Gomes, Fabio
Blackhall, Fiona H
Faivre-Finn, Corinne
Evison, M.
Affiliation
Christie Patient Centred Research, The Christie NHS Foundation Trust, Manchester, UKIssue Date
2021
Metadata
Show full item recordAbstract
Introduction: Optimal treatment for 'potentially resectable' stage III-N2 non-small cell lung cancer (NSCLC) requires multimodality treatment: local treatment (surgery or radiotherapy) and systemic anticancer therapy. There is no clear evidence of superiority for survival between the two approaches and little research has explored quality of life (QOL). This study will inform the design of a phase III randomised trial of surgery versus no surgery as part of multimodality treatment for stage III-N2 NSCLC with QOL as a primary outcome. Methods and analysis: Patient participants will be randomised to receive multimodality treatment (1) with surgery OR (2) without surgery. The Quintet Recruitment Intervention will be used to maximise recruitment. Eligible patients will have 'potentially resectable' N2 NSCLC and have received a multidisciplinary team recommendation for multimodality treatment. Sixty-six patients and their carers will be recruited from 8 UK centres. Patient/carer QOL questionnaires will be administered at baseline, weeks 6, 9, 12 and month 6. Semistructured interviews will be conducted. Quantitative data will be analysed descriptively and qualitative data will be analysed using framework analysis.Citation
Taylor S, Yorke J, Tsim S, Navani N, Baldwin D, Woolhouse I, et al. Impact on quality of life from multimodality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial). BMJ Open Resp Res. 2021 Jul;8(1):e000846.Journal
BMJ Open Respiratory ResearchDOI
10.1136/bmjresp-2020-000846PubMed ID
34266853Additional Links
https://dx.doi.org/10.1136/bmjresp-2020-000846Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/bmjresp-2020-000846
Scopus Count
Collections
Related articles
- Stage III Non-small Cell Lung Cancer: A UK National Survey of Practice.
- Authors: Evison M, Edwards J, McDonald F, Popat S
- Issue date: 2020 Aug
- Study protocol for VIdeo assisted thoracoscopic lobectomy versus conventional Open LobEcTomy for lung cancer, a UK multicentre randomised controlled trial with an internal pilot (the VIOLET study).
- Authors: Lim E, Batchelor T, Shackcloth M, Dunning J, McGonigle N, Brush T, Dabner L, Harris R, Mckeon HE, Paramasivan S, Elliott D, Stokes EA, Wordsworth S, Blazeby J, Rogers CA, VIOLET Trialists
- Issue date: 2019 Oct 14
- Surgery as a Component of Multimodality Care for Known Stage IIIA-N2 Non-small Cell Lung Cancer.
- Authors: Bograd AJ, Vallières E
- Issue date: 2020 Jun
- Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
- Authors: Zhu J, Li R, Tiselius E, Roudi R, Teghararian O, Suo C, Song H
- Issue date: 2017 Dec 16
- Advances in the use of surgery and multimodality treatment for N2 non-small cell lung cancer.
- Authors: Van Schil PE, Yogeswaran K, Hendriks JM, Lauwers P, Faivre-Finn C
- Issue date: 2017 Jun